Study finds ProbioKid reduces infections in children during winter months
MONTREAL A study presented last month before the European Respiratory Society Annual Congress determined that the branded probiotic ProbioKid reduced infectious events in children by 25% during the winter period, as compared with a placebo. The study was conducted during the winter of 2006-2007 and involved 135 healthy, school-aged children who had suffered from at least three episodes of ear-nose-throat, bronchopulmonary or gastric disorder during the course of the previous winter.
Half of the children in the probiotic group did not develop any ENT, bronchopulmonary or gastric disorder during the winter, versus 32.9% of children in the placebo group.
ProbioKid, distributed by Institut Rosell-Lallemand, contains a combination of three probiotic strains and a prebiotic.
Brioschi Pharmaceuticals to revitalize Brioschi heartburn-relief brand
FAIR LAWN, N.J. Brioschi Pharmaceuticals International last month announced its intent to revitalize the Brioschi heartburn-relief brand. The company is pitting substantial capital into a marketing plan that incorporates everything from trade promotions, sampling and healthcare professional recommendations to newspaper advertising, digital marketing and sponsorships, the company stated.
Brioschi identified the Greenwood Group to help manage the company’s growth both nationally and internationally. “[Greenwood] is a significant addition to our team,” stated Arthur Dessein, Brioschi’s VP sales. “Their industry expertise is astonishing, and they’re simply the best at what they do.”
A line extension is in the works for release in early 2011. “Brioschi is a niche product,” said Greenwood Group president Patrick O’Leary. “Consumers have a demand for it, and they will go somewhere else if they can’t find it.”
Prestige Brands completes purchase of Blacksmith Brands
IRVINGTON, N.Y. Prestige Brands Holdings on Monday announced that it has completed its previously announced purchase of Blacksmith Brands Holdings.
The transaction was finalized under the original terms announced on Sept. 20, which called for Prestige to pay $190 million in cash at closing plus a customary working capital adjustment that amounted to $13.4 million.
The purchase includes five over-the-counter healthcare products: Efferdent and Effergrip denture care products, PediaCare children’s over-the-counter medicines, Luden’s cough drops and NasalCrom allergy treatment.